01—Abstract
Summary
Summary of the 10-K filed February 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported total revenues of $1,887.1 milliona for 2023, up from $1,488.7 million in 2022, driven by net product sales of $1,860.6 million.
INGREZZA net product sales totaled $1.8 billionb in 2023 (about 99% of total net product sales), reflecting higher prescription demand, continued direct-to-consumer advertising and the expansion of the sales force completed in April 2022. Net income rose to $249.7 million ($2.47 diluted EPS) from $154.5 million in 2022, while operating income was $250.9 million. Operating expenses increased, with research and development at $565.0 million and SG&A at $887.6 million, and acquired in-process R&D of $143.9 million tied to the Voyager collaboration.
The balance sheet strengthened, with cash, cash equivalents and marketable securities of $1,719.1 millionc at December 31, 2023, versus $1,288.7 million a year earlier. Operating cash flow was $389.9 million. The company's convertible senior notes due May 2024 had $170.4 million principal outstanding, and the company elected to settle conversions in cash.
The accumulated deficit narrowed to $157.1 milliond. The company also reported Phase 3 positive top-line data for crinecerfont in adult and pediatric congenital adrenal hyperplasia, with NDA submissions expected in the second quarter of 2024, and settled all patent litigation over INGREZZA generics, with generic entry permitted beginning March 1, 2038, or earlier under certain circumstances. Key risks in the filing include reliance on a limited number of customers (four customers represented approximately 91% of 2023 product sales), dependence on federal healthcare program payors including Medicare and Medicaid, the Inflation Reduction Act's drug price negotiation provisions, reliance on third-party contract manufacturers, and the cost of pipeline programs that did not meet primary endpoints in the fourth quarter of 2023.
02—Key points
Key Highlights
- Total revenues of $1,887.1 million in 2023, up from $1,488.7 million in 2022; net product sales were $1,860.6 million.
- INGREZZA net product sales reached $1.8 billion in 2023, approximately 99% of total net product sales, and INGREZZA received FDA approval for chorea associated with Huntington's disease in August 2023.
- Net income of $249.7 million ($2.47 diluted EPS) versus $154.5 million in 2022; operating income of $250.9 million.
- Cash, cash equivalents and marketable securities of $1,719.1 million at year-end 2023, up from $1,288.7 million; operating cash flow of $389.9 million.
- Phase 3 CAHtalyst studies of crinecerfont in adults and pediatrics with CAH met primary endpoints; NDA submissions planned for the second quarter of 2024 and Breakthrough Therapy designation was granted.
- Settled all patent litigation over INGREZZA generics; generic companies may sell beginning March 1, 2038, or earlier under certain circumstances.
- Customer concentration risk: four specialty pharmacy and distribution customers accounted for approximately 91% of 2023 total product sales and approximately 98% of accounts receivable.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Neurocrine Biosciences kept $0.13.
- Revenue$1.89B100.0%
- Cost of revenue−$39.7M2.1%
- Gross profit$1.85B97.9%
- Operating costs−$1.60B84.6%
- Operating income$250.9M13.3%
- Interest, other & tax−$1.2M0.1%
- Net income$249.7M13.2%
Where FY2023 revenue went
$1.89B- SG&A: $887.6M, 47% of revenue
- Other operating costs: $708.9M, 38% of revenue
- Net income: $249.7M, 13% of revenue
- Cost of revenue: $39.7M, 2.1% of revenue
Kept 13% as net incomeNet income $249.7M · 13%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 9, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $1.89B$1.49B | +26.8% |
| Cost of Revenue | $39.70M$23.20M | +71.1% |
| Gross Profit | $1.85B$1.47B | +26.1% |
| SG&A Expenses | $887.60M$752.70M | +17.9% |
| Operating Expenses | $1.64B$1.24B | +32.0% |
| Operating Income | $250.90M$249.00M | +0.8% |
| Interest Expense | $4.60M$7.10M | −35.2% |
| Net Income | $249.70M$154.50M | +61.6% |
| EPS (Basic) | $2.56$1.61 | +59.0% |
| EPS (Diluted) | $2.47$1.56 | +58.3% |
| Shares Outstanding (Basic) | 97.70M95.80M | +2.0% |
| Shares Outstanding (Diluted) | 101.00M98.90M | +2.1% |
05—Questions
Frequently Asked Questions
How did Neurocrine's revenue and profitability change in 2023?
Total revenues rose to $1,887.1 million from $1,488.7 million, and net income increased to $249.7 million from $154.5 million. Growth was driven primarily by higher INGREZZA net product sales, which reflected higher prescription demand and increased commercial activity. Results also included $143.9 million of acquired in-process R&D tied to the expanded Voyager partnership.
What are the main drivers of INGREZZA's sales growth?
The filing attributes INGREZZA net product sales growth to higher prescription demand, continued investment in the branded direct-to-consumer advertising campaign, and benefit from the specialty sales force expansion completed in April 2022. INGREZZA net product sales were $1.8 billion in 2023, compared with $1.4 billion in 2022.
How strong is the company's balance sheet and liquidity position?
Cash, cash equivalents and marketable securities totaled $1,719.1 million at December 31, 2023, up from $1,288.7 million. Working capital was $952.2 million. The company's only significant debt was $170.4 million of 2.25% convertible senior notes due May 15, 2024, which the company elected to settle in cash upon conversion. Management stated that existing capital resources are expected to be sufficient for at least the next 12 months.
What key pipeline catalysts are expected next?
The filing cites planned NDA submissions to the FDA for crinecerfont in adults and pediatrics with CAH in the second quarter of 2024. An FDA target action date of April 30, 2024 was set for the INGREZZA oral granules NDA. Top-line data are expected in the first half of 2024 for EFMODY studies in CAH and adrenal insufficiency, and in the second half of 2024 for several Phase 2 programs. Two programs, NBI-921352 in focal onset seizures and NBI-1065846 in anhedonia, did not meet primary endpoints and will not be developed further at this time.
What are the most significant risks flagged in the filing?
The filing highlights reliance on a limited number of customers, with four accounting for about 91% of 2023 product sales. A majority of revenue comes from federal healthcare programs, including Medicare and Medicaid, making the company exposed to government pricing actions such as the Inflation Reduction Act's drug price negotiation provisions. The company also depends on third-party contract manufacturers and limited suppliers, and it has competition from AUSTEDO for tardive dyskinesia. It also has a history of losses and a $157.1 million accumulated deficit.
06—Continue